Airborne transmission is the dominant route for the spread of COVID-19
Transmission pathways of coronavirus disease 2019 (COVID-19) were studied by analyzing the trend and mitigation measures in the three epicenters. Results show that the airborne transmission route is highly virulent and dominant for the spread of COVID-19. The difference with and without mandated face covering represents the determinant in shaping the trends of the pandemic. Mitigation measures, such as social distancing implemented in the United States, are insufficient by themselves in protecting the public.

Various mitigation measures have been implemented to fight the coronavirus disease 2019 (COVID-19) pandemic, including widely adopted social distancing and mandated face covering. However, assessing the effectiveness of those intervention practices hinges on the understanding of virus transmission, which remains uncertain.

The governments’ responses to the COVID pandemic have so far differed significantly worldwide. Swift actions to the initial outbreak were undertaken in China, as reflected by nearly simultaneous implementation of various aggressive mitigation measures. On the other hand, the response to the pandemic was generally slow in the western world, and implementation of the intervention measures occurred only consecutively. Clearly, the responsiveness of the mitigation measures governed the evolution, scope, and magnitude of the pandemic globally.

Curbing the COVID-19 relies not only on decisive and sweeping actions but also, critically, on the scientific understanding of the virus transmission routes, which determines the effectiveness of the mitigation measures. In the United States, social distancing and stay-at-home measures, in conjunction with hand sanitizing, were implemented during the early stage of the pandemic (March 16). These measures minimized short-range contact transmission but did not prevent long-range airborne transmission, responsible for the inefficient containing of the pandemic in the United States.

By analysing the trend and mitigation measures in Wuhan, China, Italy, and New York City, from January 23 to May 9, 2020, authors of a recent research article published in the Proceedings of the National Academy of Sciences illustrated that the impacts of mitigation measures were discernable from the trends of the pandemic. Their analysis revealed that the difference with and without mandated face covering represents the determinant in shaping the pandemic trends in the three epicenters. Is is estimated that this protective measure alone significantly reduced the number of infections by over 78,000 in Italy from April 6 to May 9 and over 66,000 in New York City from April 17 to May 9.

Mandated face covering, such as those implemented in China, Italy, and NYC, seems to have effectively prevented airborne transmission by blocking atomization and inhalation of virus-bearing aerosols and contact transmission by blocking viral shedding of droplets. While the combined face-covering and social distancing measures offered dual protection against the virus transmission routes, the timing and sequence in implementing the measures also exhibited distinct outcomes during the pandemic.

For example, social distancing measures, including city lockdown and stay-at-home orders, were implemented well before face covering was mandated in Italy and NYC, and this sequence left an extended window (28 days in Italy and 32 days in NYC) for largely uninterrupted airborne transmission to spread the disease. The simultaneous implementation of face covering and social distancing, such as that undertaken in China, was most optimal, and this configuration, in conjunction with extensive testing and contact tracing, was responsible for the curve flattening in China.

Also, there likely existed remnants of virus transmission after the implementation of regulatory measures, because of circumstances when the measures were not practical or were disobeyed and/or imperfection of the measures. Such limitations, which have been emphasized by the WHO, spurred on controversial views on the validity of wearing face masks to prevent the virus transmission during the pandemic.

However, it is implausible that the limitations of mitigation measures alone contributed dominantly to the global pandemic trend, as exemplified by the success in China. The study suggests that the failure in containing the propagation of COVID-19 pandemic worldwide is largely attributed to the unrecognized importance of airborne virus transmission.

The inadequate knowledge on virus transmission has inevitably hindered development of effective mitigation policies and resulted in unstoppable propagation of the COVID-19 pandemic. Airborne transmission, particularly via nascent aerosols from human atomization, is highly virulent and represents the dominant route for the transmission of this disease.

While the WHO and the US Centers for Disease Control and Prevention (CDC) have emphasized the prevention of contact transmission, both WHO and CDC have largely ignored the importance of the airborne transmission route. The current mitigation measures, such as social distancing, quarantine, and isolation implemented in the United States, are insufficient by themselves in protecting the public.

The difference with and without mandated face covering represents the determinant in shaping the trends of the pandemic worldwide. We conclude that wearing of face masks in public corresponds to the most effective means to prevent interhuman transmission, and this inexpensive practice, in conjunction with extensive testing, quarantine, and contact tracking, poses the most probable fighting opportunity to stop the COVID-19 pandemic, prior to the development of a vaccine.

It is also important to emphasize that sound science should be effectively communicated to policy makers and should constitute the prime foundation in decision-making amid this pandemic. Implementing policies without a scientific basis could lead to catastrophic consequences, particularly in light of attempts to reopen the economy in many countries. Clearly, integration between science and policy is crucial to formulation of effective emergency responses by policy makers and preparedness by the public for the current and future public health pandemics.

REFERENCES:

  1. Identifying airborne transmission as the dominant route for the spread of COVID-19. Renyi Zhang, Yixin Li, Annie L. Zhang, Yuan Wang, Mario J. Molina. Proceedings of the National Academy of Sciences Jun 2020, 202009637; DOI: 10.1073/pnas.2009637117
  2. World Health Organization, Coronavirus disease (COVID-2019) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/. Accessed 9 May 2020.
  3. US Centers for Disease Control and Prevention, Coronavirus Disease 2019 (COVID-19) – Social distancing, quarantine, and isolation. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/social-distancing.html. Accessed 9 May 2020.

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »